Industry Pulse › RFK and the FDA July 2026 Peptide Decision May 24, 2026 · Regulatory Research Use Only. This article analyzes upcoming FDA regulatory activity in the context of research peptide supply chains. Genevium peptides are intended strictly for laboratory research purposes. Not approved for human consumption, clinical, therapeutic, veterinary, or diagnostic use. For …
More
RFK, the FDA, and Seven Peptides: What to Expect from the July 2026 PCAC Review
What the Peptide Sciences Shutdown Revealed: A Supplier-Side Analysis of Research Peptide Operations in 2026
Industry Pulse › What the Peptide Sciences Shutdown Revealed May 23, 2026 · Research In March 2026, Peptide Sciences voluntarily ceased operations. The company had been one of the largest U.S. research peptide suppliers for more than a decade, with an estimated $7.4 million in monthly revenue and a customer base spanning academic laboratories, independent …
More
The FDA Peptide Reclassification of 2026: What Actually Changed, What’s Pending, and What It Means for Research Suppliers
Industry Pulse › The FDA Peptide Reclassification of 2026 May 23, 2026 · Regulatory In the first half of 2026, the FDA built and deployed a framework. The framework is clinical need, and it is now the lens through which every peptide compounding question will be evaluated going forward. Three regulatory actions between February and …
More
FDA Reverses Course on Seven Peptides: PCAC Reviews BPC-157, TB-500, KPV in July
The FDA Pharmacy Compounding Advisory Committee will convene July 23-24, 2026 to consider adding BPC-157, TB-500, KPV, Semax, Epitalon and others to the 503A bulks list. If recommended, compounding pharmacies could legally prepare these compounds for the first time.
More
What “Research Use Only” Actually Means: The Legal Distinction Researchers and Buyers Keep Conflating
Research use only peptides occupy a narrow legal category that buyers and sellers increasingly treat as a generic disclaimer. As FDA enforcement intensifies in 2026, the RUO line is becoming the dividing line between legitimate laboratory commerce and federal regulatory exposure.
MoreGlow Peptide Research: BPC-157, TB-500, GHK-Cu
Research Hub › Skin & Cosmetic › Glow Peptide Research Research Use Only. The information on this page summarizes published peptide research for laboratory and educational reference. The compounds discussed are intended exclusively for in vitro and non-clinical research. Nothing on this page constitutes medical advice or describes human use, diagnosis, treatment, or therapeutic application. …
More
The Peptide Wild West Hits Mainstream Media: What the Coverage Misses About Research Suppliers
Industry Pulse › The Peptide Wild West Hits Mainstream Media May 3, 2026 · Trends In the last seven days, at least eight major outlets including Fox News, CBS News, The Hill, Medscape, and MDLinx have published variations of the same story: the peptide market is a “Wild West” where unregulated injectables, social-media hype, and …
More
FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to Know
Industry Pulse › FDA Moves to Ban Compounded Semaglutide and Tirzepatide May 1, 2026 · Regulatory On May 1, 2026, the FDA filed a proposal that would effectively end large-scale compounding of semaglutide, tirzepatide, and liraglutide in the United States. These are the active ingredients in Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda. If the …
More
Beyond Ozempic and Mounjaro: A Five-Target Obesity Drug Just Outperformed Both
A research team at Helmholtz Zentrum München has published the design of a single-molecule quintuple agonist that activates GLP-1, GIP, and three PPAR receptor subtypes. Published in Nature on April 30, 2026, the conjugate outperformed semaglutide and tirzepatide dual agonism in obese diabetic mouse models.
More